Brief: Nabla Bio Signs Second Takeda Collaboration To Advance Ai-Driven Design Of Protein Therapeutics
14/10/2025 10:00
Oct 14 (Reuters) - NABLA BIO : NABLA BIO SIGNS SECOND TAKEDA COLLABORATION TO ADVANCE AI-DRIVEN DESIGN OF PROTEIN THERAPEUTICS NABLA BIO: TO GET DOUBLE-DIGIT MILLIONS IN UPFRONT & RESEARCH COST PAYMENTS, ELIGIBLE TO GET SUCCESS-BASED PAYMENTS THAT MAY EXCEED $1 BILLION IN TOTAL Source text: [ID:] Further company coverage: 4502.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)